Clinical trials: Fatty Liver, Alcoholic
NAFLD
Effect of Consumption of Millet Diet in Patients With NAFLD
With NAFLD fast rising its ranks in becoming a major non communicable disease in India and across the globe, this study aims at primary prevention of the condition.
- Trial name
- NCT06341790
- Testing
- jowar based products
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Non-alcoholic Fatty Liver Disease
To Explore the Effectiveness of Jing-Si Herbal Tea Against Non-alcoholic Fatty Liver Disease
The aim of this study is to explore the effectiveness of Jing-Si Herbal Tea on improving the Non-alcoholic fatty liver disease patients
- Trial name
- NCT05858138
- Testing
- Jing-Si Herbal Tea
- Where
- Taiwan
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Taichung Tzu Chi Hospital
Fatty Liver
Monitoring Changes in Hepatic Steatosis Using Continuous Controlled Attenuation Parameter
Background: Non-alcoholic fatty liver disease (NAFLD) affects 30% of the Asian adult population and is emerging as one of the important leading causes of liver cancer and cirrhosis.
- Trial name
- NCT06203548
- Testing
- Lifestyle modification programme
- Where
- Hong Kong
- Volunteers
- 150 people
- Sponsor
- Chinese University of Hong Kong
Non Alcoholic Fatty Liver
Assessment of Nonalcoholic Fatty Liver Disease in Diabetic and Prediabetic Patients Using Noninvasive Methods.
assessment of NAFLD among diabetic, pre-diabetic and non diabetic participants Using Non Invasive Methods.And correlation between lab and radiological methods .
- Trial name
- NCT04553796
- Testing
- fibroscan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Assiut University
Nonalcoholic Fatty Liver
Effect of Adding TENS to Mediterranean Diet on Appetite and Liver Enzymes in Nonalcoholic Fatty Liver Patients
This study aims to identify the effect of adding TENS to the Mediterranean diet on appetite and liver enzymes in Nonalcoholic fatty liver patients.
- Trial name
- NCT07200934
- Testing
- Transcutaneous electrical stimulation (TENS), Mediterranean Diet
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
Liver Disease, Fatty Liver
Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Background: Metabolism refers to the many chemical pathways by which various compounds, including food, are processed and used in the body.
- Trial name
- NCT02520609
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nonalcoholic Fatty Liver Disease (NAFLD)
Anti-LPS Antibody Treatment for Pediatric NAFLD
The main objective of this pilot study is to evaluate whether 12 weeks of IMM-124E in children with nonalcoholic fatty liver disease (NAFLD) in combination with standard of care treatment will decrease inflammation in the liver…
- Trial name
- NCT03042767
- Testing
- IMM-124E
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Miriam Vos, MD
NAFLD
Serum Selenium and Zinc Levels in Non-alcoholic Fatty Liver Disease Patients
Non-alcoholic fatty liver disease (NAFLD) includes a wide range of disorders that consist of simple fatty infiltration, steatohepatitis (NASH), and end-stage liver disease (cirrhosis).
- Trial name
- NAFLD (NCT04834063)
- Testing
- Serum Zinc a level, serum selenium level, Fibroscan measurement
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sohag University
Nonalcoholic Fatty Liver Disease
Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic fatty liver disease (NAFLD) is the most common type of liver disease in the United States. The incidence of NAFLD is very similar to that of obesity, type 2 diabetes, and the metabolic syndrome.
- Trial name
- NCT00983463
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Vanderbilt University
Non-alcoholic Steatohepatitis
A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations
Novo Nordisk is developing a combination of 2 medicines (NNC0194-0499 and semaglutide) for the treatment of nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT05766709
- Testing
- NNC0194-0499, Semaglutide, NNC0194-0499/Semaglutide A (40/3.20 mg/mL)
- Where
- Canada
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Participants
Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects
This study will evaluate safety, tolerability, and Pharmacokinetics (PK) of ID119031166M with the Exploration of Pharmacodynamic (PD) effects in Healthy Participants.
- Trial name
- NCT05604287
- Testing
- ID119031166M
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
Does the novel drug decrease liver fat in subjects with NASH or NAFLD as compared to placebo
- Trial name
- NCT02605616
- Testing
- AZ compound
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- University of Alabama at Birmingham
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Nonalcoholic Fatty Liver Disease - Intermittent Calorie Restriction (FLICR) Study
Several diets have been proposed to reduce liver steatosis in patients with nonalcoholic fatty liver disease (NAFLD), and various effects on liver steatosis have been observed.
- Trial name
- NCT05309642
- Testing
- Intermittent calorie restriction, Standard of care
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Ewha Womans University Mokdong Hospital
Type 2 Diabetes
Longitudinal Assessment of Multiple Organs in Patients With Type 2 Diabetes
MODIFY study is a multi-centre prospective, longitudinal, observational cohort study which aims to recruit 150 adult patients with type 2 diabetes recruited from community, primary care or secondary care settings.
- Trial name
- MODIFY (NCT04114682)
- Testing
- Multi parametric MRI scan
- Where
- 4 sites in United Kingdom
- Volunteers
- 135 people
- Sponsor
- Perspectum
Non Alcoholic Fatty Liver Disease
Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
Fatty liver disease is an increasingly recognized health problem in patients with type 2 diabetes mellitus (T2DM). Sodium glucose co-transporter type 2 (SGLT-2) inhibitors are a new class of anti-diabetic agents that cause weight…
- Trial name
- E-LIFT (NCT02686476)
- Testing
- Empagliflozin
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Medanta, The Medicity, India
NAFLD
Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals
The investigators will conduct a proof-of-principle 4-weeks low-calorie diet (LCD) intervention study in low birth weight (LBW) subjects and normal birth weight (NBW) controls with documented (MR scan) liver fat content equal to…
- Trial name
- NCT05842850
- Testing
- Caloric restriction intervention, No intervention
- Where
- 2 sites in Denmark
- Volunteers
- 8 people
- Sponsor
- Steno Diabetes Center Copenhagen
Non.Alcoholic Fatty Liver Disease
Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of disorders characterized by predominantly macrovesicular hepatic steatosis occurring in individuals in the absence of significant alcohol consumption.
- Trial name
- NCT01623024
- Testing
- Vitamin D, Lifestyle counseling
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- University of Palermo
Fatty Liver Disease
Effect of Thyroid Disorders in Liver Diseases
Aims of the Research 1. To detect correlation between hyperthyroidism and non alcoholic fatty liver disease (NAFLD). 2. To detect hepatic risk in subclinical and clinical hypothyroidism . 3.
- Trial name
- NCT06071923
- Testing
- Fibroscan
- Volunteers
- 140 people
- Sponsor
- Assiut University
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of MGL-3196 and its major metabolite (MGL-3623) following administration of multiple oral doses (QD x 6 days) in subjects with varying…
- Conditions
- Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
- Trial name
- NCT04643795
- Testing
- MGL-3196
- Where
- 3 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2
Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages
Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide and is a major cause of cirrhosis and liver cancer in Western countries.
- Trial name
- NCT04241575
- Testing
- Simple fibrosis scores and electronic reminder messages
- Where
- Hong Kong
- Volunteers
- 1,061 people
- Sponsor
- Chinese University of Hong Kong